A total of 150 patients with a mean age of 10.3 [0.2-21.0] were included. Patients treated for high-risk neuroblastoma and localized Ewing sarcoma with both high-dose cyclophosphamide and doxorubicin required the most platelet transfusions during the course of treatment, with an average of 13 and 13 transfusions, respectively. he was 9 times. Partly due to CIT, it was greatest in patients treated for high- and intermediate-risk rhabdomyosarcoma. Fifty-six percent of high-risk patients had an RDI decrease in the last two treatment cycles, and 69% of intermediate-risk patients had an RDI decrease in the last four treatment cycles.
• Benzoates
• Hydrazine
• Pyrazoles
• Cisplatin
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
